LONDON – AstraZeneca has launched a new global health technology company, Evinova, after seeing a gap in the market to reduce the length and cost of clinical trials while making the process easier for patients.
Financially backed by AstraZeneca but operating as a separate company, Evinova will provide global services to CROs and pharmaceutical companies to design, conduct and monitor clinical trials. Evinova will charge customers for access to its technology, operating on a revenue-based model.
Unlock this article instantly by becoming a free subscriber.
You’ll have access to free articles every month and you can personalize the newsletters delivered to your inbox each week, including the latest news.
